The Supreme Court concluded that it simply makes sense that a generic manufacturer be able to challenge a brand company’s patent use code for incorrectly describing the patented method of using the drug.
In its unanimous April 17 ruling in Caraco Pharmaceutical Laboratories Ltd. v. Novo Nordisk A/S, the court...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?